Table 1.
Patient, donor, and transplant characteristics
| Characteristics | No DSAs (n = 4157) | DSAs (n = 567) | P‐value | Total cohort (N = 4724) |
|---|---|---|---|---|
| Patient | ||||
| Age at transplant, y, mean ± SD | 45.6 ± 14.4 | 44.2 ± 13.9 | .01a | 45.4 ± 14.4 |
| Female sex, n | 1561 (37.6) | 333 (58.7) | <.001b | 1894 (40.1) |
| PRA at time of transplant, %, mean ± SD | 3.5 ± 12.9 | 24.4 ± 30.7 | <.001a | 6.0 ±17.5 |
| Highest PRA, %, mean ± SD | 9.8 ± 21.0 | 43.6 ± 36.3 | <.001a | 13.8 ± 25.8 |
| Dialysis | .0004b | |||
| No, n (%) | 472 (1.4) | 43 (7.6) | 515 (10.9) | |
| Yes—hemodialysis, n | 2140 (51.4) | 332 (58.6) | 2472 (52.3 ) | |
| Yes—peritoneal dialysis, n | 1529 (36.8) | 186 (32.8) | 1715 (36.3) | |
| Unknown, n (%) | 16 (0.4) | 6 (1.1) | 22 (0.5) | |
| Time on dialysis, y, mean ± SD | 2.7 ± 2.4 | 3.4 ± 3.0 | <.0001a | 2.8 ± 2.5 |
| Donor | ||||
| Donor age, y, mean ± SD | 44.4 ± 14.9 | 44.0 ± 15.8 | 1.00a | 44.4 ± 15.0 |
| Donor female sex, n | 2128 (51.2) | 258 (45.5) | .01b | 2386 (50.5) |
| Type of donor | <.001b | |||
| Living, n | 1350 (32.5) | 137 (24.2) | 1487 (31.4) | |
| Deceased—DBD, n | 2076 (49.9) | 351 (61.9) | 2427 (51.4) | |
| Deceased—DCD, n (%) | 731 (17.6) | 79 (13.9) | 810 (17.2) | |
| Cold ischemia time | ||||
| Deceased donors, h, mean ± SD | 21.7 ± 7.3 | 22.8 ± 6.8 | .001a | 21.9 ± 7.2 |
| Living donors, h, mean ± SD | 2.5 ± 1.6 | 2.5 ± 1.0 | .53 a | 2.5 ± 1.5 |
| Transplant | ||||
| Retransplant, n (%) | 453 (10.9) | 270 (47.6) | <.001b | 723 (15.3) |
| HLA‐A/B/DR broad mismatches, mean ± SD | 2.3 ± 1.5 | 2.4 ± 1.3 | .15a | 2.4 ± 1.5 |
| Induction therapy | ||||
| IL‐2 receptor blocker, n (%) | 913 (21.9) | 109 (19.2) | .14b | 1022 (21.6) |
| T cell–depleting antibody,cn (%) | 145 (3.6) | 39 (6.9) | <.001b | 184 (3.9) |
| Initial immunosuppression, n (%) | ||||
| Steroids | 4069 (97.9) | 547 (96.5) | .04b | 4616 (97.7) |
| MMF/azathioprine | 3163 (76.1) | 442 (78) | .20b | 3605 (76.3) |
| Cyclosporine/tacrolimus | 3892 (93.6) | 542 (95.6) | .07b | 4434 (93.9) |
| Sirolimus | 260 (6.3) | 26 (4.6) | .12b | 286 (6.1) |
| Other | 555 (13.4) | 53 (9.4) | .008b | 608 (12.9) |
| Unknown | 14 (0.3) | 3 (0.5) | .47b | 17 (0.4) |
DBD, donation after brain death; DCD, donation after cardiac death; DSA, donor‐specific HLA antibody; IL, interleukin; MMF, mycophenolate mofetil.
a
Mann–Whitney U test for continuous variables.
b
χ2 test for categorical variables.
c
T cell–depleting antibody therapy: ALG, ATG, OKT3 monoclonal antibodies.